19036-73-8

Basic information

• Product Name: (S)-1-(3-TRIFLUOROMETHYLPHENYL)-2-AMINOPROPANE
• Synonyms: (S)-1-(3-TRIFLUOROMETHYLPHENYL)-2-AMINOPROPANE;(S)-1-(3-TRIFLUOROMETHYLPHENYL)-2-PROPANAMINE;(S)-alpha-methyl-m-(trifluoromethyl)phenethylamine;(S)-α-Methyl-3-(trifluoromethyl)benzeneethanamine;[S,(+)]-α-Methyl-3-(trifluoromethyl)benzeneethanamine;[S,(+)]-α-Methyl-m-(trifluoromethyl)phenethylamine;Dexnorfenfluramine;Nordexfenfluramine
• CAS NO: 19036-73-8
• Molecular Formula: C₁₀H₁₂F₃N
• Molecular Weight: 203.2
• EINECS: 242-769-7
• Mol File: 19036-73-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 215.2°Cat760mmHg
• Flash Point: 88.9°C
• Appearance: /
• Density: 1.152g/cm³
• CAS DataBase Reference: (S)-1-(3-TRIFLUOROMETHYLPHENYL)-2-AMINOPROPANE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-(3-TRIFLUOROMETHYLPHENYL)-2-AMINOPROPANE(19036-73-8)
• EPA Substance Registry System: (S)-1-(3-TRIFLUOROMETHYLPHENYL)-2-AMINOPROPANE(19036-73-8)

Safety Data

• Hazardous Substances Data: 19036-73-8(Hazardous Substances Data)

Usage

General Description

(S)-1-(3-trifluoromethylphenyl)-2-aminopropane, also known as (S)-TFMSPP, is a chemical compound with the molecular formula C9H12F3N. It is a chiral compound, meaning it has a non-superimposable mirror image. (S)-1-(3-TRIFLUOROMETHYLPHENYL)-2-AMINOPROPANE is a selective dopamine reuptake inhibitor, meaning it has the potential to affect dopamine levels in the brain. It is also a potential candidate for the treatment of various neurological and psychiatric conditions. Additionally, (S)-TFMSPP can be used as a research tool in the study of neurotransmitter systems and as a reference standard for analytical studies. However, due to its potential effects on dopamine levels, it should be handled and used with caution and under appropriate safety measures.

Upstream product

• 58225-71-1 (S),(S)-N-(1-phenylethyl)-α-methyl-3-(trifluoromethyl)benzeneethanamine 
• 213202-12-1 (S)-N-((S)-1-phenylethyl)-1-(3-(trifluoromethyl)phenyl)propan-2-amine 
• 7440-05-3 palladium 
• 21906-39-8 3-(trifluoromethyl)phenylacetone 
• 213682-62-3 2-[(S)-1-Methyl-2-(3-trifluoromethyl-phenyl)-ethyl]-isoindole-1,3-dione 
• 135561-78-3 (R)-1-(3’-trifluoromethylphenyl)-2-propanol 
• 135561-75-0 1-[(3′-trifluoromethyl)phenyl]-2-propanol 

Relevant articles and documents

METHOD FOR TREATING EPILEPSY

In certain embodiments, the present disclosure is directed to methods and uses for treating a mammal having an epileptic seizure disorder or being at risk for having an epileptic seizure disorder, comprising administering certain herein disclosed isolated fenfluramine enantiomers that are surprisingly effective as anti-epilepsy drugs (AEDs), despite having lower anti-seizure potency than fenfluramine racemate, by virtue of also being less cardiotoxic than fenfluramine racemate. Preferred embodiments contemplate treatment of Dravet syndrome; other preferred embodiments contemplate treatment of other epileptic seizure disorders.

Process for the production of the isomers (R) and (S)-α-methyl-3(trifluoromethyl)benzeneethanamine

Process for the production of the isomers (R) and (S)-α-methyl-3-(trifluoromethyl)benzeneethanamine, the second being useful as intermediate in the synthesis of the anorexic drug dexfenfluramine (INN), which comprises carrying out a stereospecific reductive amination of 1-(3-trifluoromethyl)phenyl-2-propanone with (R) or (S)-α-methylbenzylamine under a hydrogen atmosphere in the presence of a catalyst and debenzylating the resulting diastereoisomer (R),(R) or (S),(S)-N-(1-phenylethyl)-α-methyl-3-(trifluoromethyl)benzeneethanamine by treatment with hydrogen and a catalyst.